信邦製藥(002390.SZ):琪康國際及一致行動人已減持999.96萬股 提前終止減持計劃
格隆匯3月24日丨信邦製藥(002390.SZ)公佈,公司股東琪康國際及一致行動人嘉興海東清、Healthy Angel原擬自2019年10月12日披露減持公告之日起15個交易日後的6個月內以集中競價方式減持公司股份不超過3334.46萬股,即不超過公司總股本的2.00%。
公司於2020年3月24日收到琪康國際及一致行動人嘉興海東清、Healthy Angel出具的《關於提前終止減持計劃的告知函》,上述股東決定提前終止其股份減持計劃。截至2020年3月23日,上述股東通過集中競價方式減持公司股份999.96萬股,佔公司總股本的0.5998%。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.